Ivermectin as Prophylaxis Against COVID-19 Retrospective Cases Evaluation
Hirsch et al., Microbiology & Infectious Diseases
Hirsch et al., Ivermectin as Prophylaxis Against COVID-19 Retrospective Cases Evaluation, Microbiology & Infectious Diseases
Report on ivermectin prophylaxis for healthcare workers in a hospital in Argentina, showing 0 cases in the 162 participants. Dosage was 0.2mg/kg weekly for eight weeks, followed by 4 months rest.
Hirsch et al., 6 Jan 2021, peer-reviewed, 2 authors.
Abstract: Review Article
ISSN 2639-9458
Microbiology & Infectious Diseases
Ivermectin as Prophylaxis Against COVID-19 Retrospective Cases Evaluation
Hirsch, Roberto R1* and Carvallo, Hector E2
Former Professor of Infectology, University of Buenos Aires,
Argentina.
Director Career for Infectology Specialist, Hospital F. J. Muñíz,
Argentina.
Director Department of Infectious Diseases, Hospital F. J. Muñíz,
Argentina.
1
Former Professor of Internal Medicine, University of Buenos
Aires, Argentina.
Former Director of Ezeiza´s Public Hospital, Argentina.
Professor of Internal Medicine, Universidad Abierta
Interamericana, Argentina.
2
*
Correspondence:
Roberto R Hirsch, Former Professor of Infectology, University
of Buenos Aires, Argentina, E-mail: rrhirsch@intramed.net.
Received: 29 November 2020; Accepted: 22 December 2020
Citation: Hirsch RR, Carvallo, Héctor E. Ivermectin as Prophylaxis Against COVID-19 Retrospective Cases Evaluation. Microbiol
Infect Dis. 2020; 4(4): 1-8.
ABSTRACT
The current SARS COV2 (COVID 19) pandemic has generated a high number of infections among Health Agents.
Around 25% of them have had to leave - temporarily or permanently - their jobs, due to having contracted the
disease.
Likewise, numerous deaths have been lamented within this group, which acts as the first defense against this and
other pathologies that threaten the individual.
All this has happened despite Personal Protective Equipments (PPEs), which makes it essential to optimize -from
the pharmacological point of view- these elements, in order to reduce the risk of contagion as much as possible.
In this sense, Ivermectin has shown its usefulness against SARS COV2, both in treatment and in prophylaxis.
Therefore, this work compiles the characteristics of the group of Health Agents (and their close contacts) from
a Buenos Aires Hospital specialized in Infectious Diseases, who resorted to it, as well as the results that were
obtained.
Keywords
protein S (spike) [1].
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit